Doxorubicin-loaded chitosan–silver nanocarrier elicits chemoresistance in liver cancer cells
Medical Oncology · 2026
DOI: 10.1007/s12032-026-03358-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Oncology, 2026. Verfasst von Ebru Başak Başbüyük und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Faculty of Science, Erzurum Technical University, Erzurum, Türkiye. Hauptthemen laut MEDLINE: Chitosan, Doxorubicin, Silver, Liver Neoplasms. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Doxorubicin (Dox) remains a cornerstone chemotherapeutic for hepatocellular carcinoma (HCC), yet its efficacy is constrained by systemic toxicity and intrinsic chemoresistance. Nanocarrier systems are proposed to overcome these limitations. This study aimed to develop and evaluate a chitosan-silver nanoparticle (Cs-AgNPs) system as a Dox delivery vehicle in HepG2 cells. Cs-AgNPs+Dox nanoparticles were synthesized and characterized by FTIR, XRD, and SEM. Drug-loading efficiency, release kinetics, and cytotoxicity were assessed and compared with those of free Dox. The modulation of PI3K/AKT/mTOR, NF-κB, autophagy, and apoptosis pathways was investigated using RT-qPCR and Western blotting. The formulation produced spherical, stable nanoparticles with high encapsulation efficiency and sustained release. Unexpectedly, at sub-toxic concentrations (6.25-50 µg/mL), Cs-AgNPs+Dox exhibited significantly lower cytotoxicity than free Dox. Mechanistic studies revealed strong activation of the PI3K/AKT/mTOR and NF-κB signaling cascades, accompanied by upregulation of autophagy markers (LC3, Beclin1) and reduced Caspase-3 expression. These findings indicate that the nanocarrier itself induces a pro-survival, chemoresistant phenotype in HepG2 cells. Cs-AgNPs is not an inert carrier but an active biological modulator that can antagonize Dox-induced cytotoxicity by stimulating key survival and autophagy pathways. This work underscores the importance of assessing the intrinsic bioactivity of metallic polymer hybrid nanocarriers, as their inadvertent compromise of therapeutic efficacy is a concern. Future optimization should integrate pathway-specific inhibitors to mitigate nanocarrier-induced resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Faculty of Science, Erzurum Technical University, Erzurum, Türkiye.
- High Technology Application and Research Center (YÜTAM), Erzurum Technical University, Erzurum, Türkiye.
- Department of Molecular Biology and Genetics, Faculty of Science, Erzurum Technical University, Erzurum, Türkiye. mesut.akyuz@erzurum.edu.tr.
- High Technology Application and Research Center (YÜTAM), Erzurum Technical University, Erzurum, Türkiye. mesut.akyuz@erzurum.edu.tr.
- Department of Molecular Biology and Genetics, Faculty of Science, Atatürk University, Erzurum, Türkiye.
- East Anatolia High Technology Application and Research Center (DAYTAM), Atatürk University, Erzurum, Türkiye.
ORCID-Profile: Mesut Akyüz
Zitieren
APA
Başbüyük, E. B., Akyüz, M., Solak, K., & Kara, A. (2026). Doxorubicin-loaded chitosan–silver nanocarrier elicits chemoresistance in liver cancer cells. Medical Oncology. https://doi.org/10.1007/s12032-026-03358-8
Vancouver
Başbüyük EB, Akyüz M, Solak K, Kara A. Doxorubicin-loaded chitosan–silver nanocarrier elicits chemoresistance in liver cancer cells. Medical Oncology. 2026. doi:10.1007/s12032-026-03358-8
BibTeX
@article{Babyk2026,
author = {Başbüyük, Ebru Başak and Akyüz, Mesut and Solak, Kübra and Kara, Adem},
title = {Doxorubicin-loaded chitosan–silver nanocarrier elicits chemoresistance in liver cancer cells},
journal = {Medical Oncology},
year = {2026},
doi = {10.1007/s12032-026-03358-8}
}
EUVIMED